Tracking cancer cells during chemo
Treatments studied
Part of Cancer clinical trials.
This trial studies how proteins on circulating tumor cells change during chemotherapy in people with colorectal cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to get up and care for yourself (ECOG score 0-2)
- Your doctor says you are healthy enough for chemotherapy
- You do not have an active infection before starting the trial
- You have not had another cancer in the last 3 years (except some skin cancers)
- You do not have a second colorectal cancer that started at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
This trial tests whether adding an anti-EGFR drug to standard chemotherapy helps people with right-sided advanced colorectal cancer that has not had chemotherapy before. You need to have a specific gene pattern (no RAS mutation and high AREG/EREG) to join.
This trial studies tumor samples from people with metastatic colorectal cancer to understand why treatments stop working. It aims to find new ways to target cancer that has become resistant.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
This study looks at how the immune system around a colorectal tumor relates to resistance to chemotherapy. You may be able to join if you are having surgery soon for colorectal cancer and have not yet had chemotherapy before surgery.
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Hear when a new Objective Responsive Rate (ORR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.